• EpicentRx Granted New Composition of Matter Patent for Its TGF-ß Trap Fusion Protein

    12 days ago - By San Diego Biotechnology

    LA JOLLA, Calif.: LA JOLLA, Calif., Nov. 22, 2021 /PRNewswire/ - EpicentRx, Inc., a clinical-stage biotechnology company at the forefront of oncolytic viruses and small molecules for the treatment of cancer and other inflammatory-driven diseases, today announced that the United States Patent and Trademark Office has issued U.S. Patent...
    Read more ...